Carey K. Anders, MD, concludes with a look toward the future of HER2+ breast cancer treatment and provides advice to community oncologists treating patients with breast cancer.
Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic
Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.
Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer
Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.
Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.
T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer
The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.
Strategizing ADC Use to Enhance Breast Cancer Outcomes
Paolo Tarantino, MD, PhD, discusses sequencing ADCs, managing cross-resistance, and understanding ADC composition for patients with breast cancer.